HK1125943A1 - Immunostimulatory sequence oligonucleotides and methods of using the same - Google Patents
Immunostimulatory sequence oligonucleotides and methods of using the sameInfo
- Publication number
- HK1125943A1 HK1125943A1 HK09104499.9A HK09104499A HK1125943A1 HK 1125943 A1 HK1125943 A1 HK 1125943A1 HK 09104499 A HK09104499 A HK 09104499A HK 1125943 A1 HK1125943 A1 HK 1125943A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- same
- sequence oligonucleotides
- immunostimulatory sequence
- immunostimulatory
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43612202P | 2002-12-23 | 2002-12-23 | |
US44788503P | 2003-02-13 | 2003-02-13 | |
US46754603P | 2003-05-01 | 2003-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1125943A1 true HK1125943A1 (en) | 2009-08-21 |
Family
ID=32686090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09104499.9A HK1125943A1 (en) | 2002-12-23 | 2009-05-18 | Immunostimulatory sequence oligonucleotides and methods of using the same |
Country Status (18)
Country | Link |
---|---|
US (1) | US7745606B2 (de) |
EP (2) | EP1575977B1 (de) |
JP (2) | JP5102959B2 (de) |
KR (3) | KR101309501B1 (de) |
CN (2) | CN101693890B (de) |
AT (2) | ATE544772T1 (de) |
AU (1) | AU2003297483B2 (de) |
CA (1) | CA2511475C (de) |
CY (2) | CY1109642T1 (de) |
DE (1) | DE60329223D1 (de) |
DK (2) | DK1992635T3 (de) |
ES (2) | ES2381309T3 (de) |
HK (1) | HK1125943A1 (de) |
NZ (1) | NZ541027A (de) |
PT (2) | PT1992635E (de) |
SG (2) | SG2011035342A (de) |
SI (1) | SI1575977T1 (de) |
WO (1) | WO2004058179A2 (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
KR100917101B1 (ko) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | 플렉시블 금속적층체 및 그 제조방법 |
EP2423335B1 (de) * | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür |
SG177000A1 (en) * | 2001-08-17 | 2012-01-30 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
US7956043B2 (en) * | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
EP1575977B1 (de) * | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung |
PL1794174T3 (pl) * | 2004-09-01 | 2012-11-30 | Dynavax Tech Corp | Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności |
US8072945B2 (en) | 2004-09-24 | 2011-12-06 | Aes Corporation | Link layered networks |
JP2008000001A (ja) * | 2004-09-30 | 2008-01-10 | Osaka Univ | 免疫刺激オリゴヌクレオチドおよびその医薬用途 |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
EP1841777B1 (de) * | 2005-01-28 | 2015-09-30 | Kwon, Hyung-Joo | Von mycobacterium abgeleitete oligonukleotide zur stimulierung der immunfunktion, zur behandlung von mit dem immunsystem in zusammenhang stehenden krankheiten, zur behandlung von atopischer dermatitis und/oder zum schützen normaler immunzellen |
CA2600036A1 (en) | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
JP2008535859A (ja) * | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 感染症によって悪化した喘息を治療するための方法 |
ES2435531T3 (es) | 2005-07-01 | 2013-12-20 | Index Pharmaceuticals Ab | Modulación de la capacidad de respuesta a los esteroides |
PT2269622E (pt) | 2005-07-01 | 2014-03-20 | Index Pharmaceuticals Ab | Oligonucleotídeos cpg utilizados para aumentar a actividade dos esteróides num doente dependente de esteróides |
CA2523032A1 (en) * | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
EP1940472A1 (de) | 2005-10-28 | 2008-07-09 | Index Pharmaceuticals AB | Zusammensetzung und verfahren zur prävention, behandlung und/oder linderung einer entzündlichen erkrankung |
EP2005161B1 (de) * | 2006-03-17 | 2016-02-24 | NewSouth Innovations Pty Limited | Elektrochemischer sensor |
JP5161770B2 (ja) | 2006-05-31 | 2013-03-13 | 東レ株式会社 | 免疫刺激オリゴヌクレオチド及びその医薬用途 |
EP2094849B1 (de) | 2006-11-09 | 2014-01-08 | Dynavax Technologies Corporation | Langfristige modifikation einer erkrankung mithilfe immunstimulatorischer oligonukleotide |
KR20100053598A (ko) | 2007-08-01 | 2010-05-20 | 이데라 파마슈티칼즈, 인코포레이티드 | Tlr9의 신규한 합성 효능제 |
EP2187961A2 (de) * | 2007-08-21 | 2010-05-26 | Dynavax Technologies Corporation | Zusammensetzung und verfahren zur herstellung und verwendung von influenzaproteinen |
ES2588705T3 (es) | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
EP2209896B1 (de) | 2007-10-26 | 2017-03-01 | Dynavax Technologies Corporation | Verfahren und zusammensetzungen zur hemmung von immunantworten und autoimmunität |
CA2724418A1 (en) * | 2008-05-15 | 2009-11-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
ES2524699T3 (es) | 2008-06-05 | 2014-12-11 | Immunovaccine Technologies Inc. | Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba |
EP2408306A4 (de) * | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | Substituierte nukleosid- und nukleotid-analoga |
EP2572706A4 (de) * | 2010-04-21 | 2014-02-26 | Univ Hokkaido Nat Univ Corp | Lipidmembranenstruktur mit nukleinsäure-transportfähigkeit |
AU2011258156B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
KR101810593B1 (ko) | 2010-06-16 | 2017-12-22 | 다이나박스 테크놀로지 코퍼레이션 | Tlr7 및/또는 tlr9 억제제를 사용하는 치료 방법 |
NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012068295A1 (en) * | 2010-11-16 | 2012-05-24 | Selecta Biosciences, Inc. | Immunostimulatory oligonucleotides |
EP2471926A3 (de) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunstimulierende Oligodeoxynukleotide |
CN103796673A (zh) * | 2011-04-15 | 2014-05-14 | 国立大学法人大阪大学 | Dna疫苗 |
TR201808393T4 (tr) | 2011-05-26 | 2018-07-23 | Intervet Int Bv | İmmünostimülatör oligodeoksinükleotitler. |
JP5872684B2 (ja) * | 2011-05-26 | 2016-03-01 | インターベット インターナショナル ベー. フェー. | 免疫刺激性オリゴデオキシヌクレオチド |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
EP2794630A4 (de) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | Substituierte phosphorthioat-nukleotidanaloga |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
CN102719436A (zh) * | 2012-06-27 | 2012-10-10 | 南开大学 | 一种寡核苷酸及其制备在防治心肌肥大与心力衰竭药物中的用途 |
JP6001974B2 (ja) | 2012-09-21 | 2016-10-05 | アンジェスMg株式会社 | アポリポプロテイン(a)の特異的エピトープを含むDNAワクチン |
CN106535876B (zh) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用 |
JP2017537619A (ja) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | 球状核酸ナノ粒子複合体の配列特異的細胞内取込 |
JP6715775B2 (ja) * | 2014-12-25 | 2020-07-01 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 非凝集性免疫賦活化オリゴヌクレオチド |
RU2017145940A (ru) * | 2015-05-29 | 2019-07-02 | Дайнэвокс Текнолоджиз Корпорейшн | Внутрилегочное введение полинуклеотидных агонистов толл-подобного рецептора 9 для лечения рака легких |
EP3302501B1 (de) | 2015-05-29 | 2021-09-22 | Merck Sharp & Dohme Corp. | Kombination aus einem pd-1-antagonisten und cpg-c-typ-oligonukleotid zur behandlung von krebs |
RU2017145559A (ru) * | 2015-05-29 | 2019-07-03 | Мерк Шарп И Доум Корп. | Комбинация антитела к il-10 и олигонуклеотида типа cpg-c для лечения рака |
CN106256905B (zh) * | 2015-11-24 | 2019-08-13 | 华中农业大学 | 一种对草鱼有免疫增强活性的CpG ODN序列及其应用 |
CN105567782B (zh) * | 2016-01-29 | 2020-08-04 | 山东省农业科学院畜牧兽医研究所 | 鸡胚成纤维细胞在体外筛选CpG寡聚脱氧核苷酸活性分子中的应用 |
SG11201808913WA (en) * | 2016-04-15 | 2018-11-29 | Dynavax Tech Corp | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
JP7200093B2 (ja) * | 2016-09-15 | 2023-01-06 | アイデラ・ファーマシューティカルズ,インコーポレーテッド | がん治療用tlr9アゴニストを用いた免疫調節 |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
WO2019200238A1 (en) | 2018-04-14 | 2019-10-17 | Dynavax Technologies Corporation | Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer |
WO2020081398A1 (en) | 2018-10-14 | 2020-04-23 | Dynavax Technologies Corporation | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer |
US20220241321A1 (en) * | 2019-05-10 | 2022-08-04 | Microbio (Shanghai) Co., Ltd. | Dimeric cpg oligonucleotides for use in modulating immune responses |
CN113058033A (zh) * | 2019-12-16 | 2021-07-02 | 远大赛威信生命科学(南京)有限公司 | 一种用于预防和治疗乙型肝炎的药物组合物及其用途 |
CN113122541A (zh) | 2019-12-31 | 2021-07-16 | 财团法人工业技术研究院 | 核酸药物复合体以及其用途 |
WO2023081486A1 (en) | 2021-11-08 | 2023-05-11 | Nurix Therapeutics, Inc. | Toll-like receptor therapy combinations with cbl-b inhibitor compounds |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5015733A (en) | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US5093232A (en) | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
US4910300A (en) | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
US5460831A (en) | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
JPH04352724A (ja) * | 1990-07-27 | 1992-12-07 | Mitsui Toatsu Chem Inc | 免疫調節型治療剤 |
US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
EP0879284B1 (de) | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. |
DE19631919C2 (de) * | 1996-08-07 | 1998-07-16 | Deutsches Krebsforsch | Anti-Sinn-RNA mit Sekundärstruktur |
ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
ATE441432T1 (de) | 1997-03-10 | 2009-09-15 | Ottawa Hospital Res Inst | Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
JP2001526688A (ja) | 1997-05-19 | 2001-12-18 | メルク エンド カンパニー インコーポレーテッド | オリゴヌクレオチドアジュバント |
EP1003531B1 (de) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
CA2291483C (en) | 1997-06-06 | 2012-09-18 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6157654A (en) * | 1997-06-24 | 2000-12-05 | Alcatel Networks Corporation | Adaptive service weight assignments for ATM scheduling |
EP1009413B1 (de) | 1997-09-05 | 2007-02-14 | The Regents Of The University Of California | Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
JPH11209289A (ja) | 1998-01-22 | 1999-08-03 | Taisho Pharmaceut Co Ltd | 粘膜免疫誘起剤 |
ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
EP1733735B1 (de) | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Verfahren und Produkte zur Induktion von mukosaler Immunität |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
WO2000006588A1 (en) | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
US20020065236A1 (en) * | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
EP1832657B1 (de) * | 1998-09-09 | 2012-10-24 | Genzyme Corporation | Methylierung von Plasmid-Vektoren |
DE69931377T2 (de) | 1998-09-18 | 2007-05-10 | Dynavax Technologies Corp., Berkeley | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
AU6425999A (en) | 1998-10-09 | 2000-05-01 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
US6424622B1 (en) * | 1999-02-12 | 2002-07-23 | Nec Usa, Inc. | Optimal buffer management scheme with dynamic queue length thresholds for ATM switches |
US6647011B1 (en) * | 1999-02-22 | 2003-11-11 | Marconi Communications, Inc. | Method and system for switching using an arbitrator |
US6628668B1 (en) * | 1999-03-16 | 2003-09-30 | Fujitsu Network Communications, Inc. | Crosspoint switch bandwidth allocation management |
WO2000054803A2 (en) | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
EP1176966B1 (de) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion |
EP1177439B1 (de) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening nach modulatoren der funktion von immunstimulatorischer dna |
CA2372960C (en) | 1999-05-06 | 2006-03-28 | The Immune Response Corporation | Hiv immunogenic compositions and methods |
EP2314693A3 (de) | 1999-08-13 | 2012-11-28 | Idera Pharmaceuticals, Inc. | Modulierung der durch CpG-oligonukleotide verursachte Immunstimulierung durch positionsbedingte Veränderung von Nukleosiden |
ATE419869T1 (de) * | 1999-08-19 | 2009-01-15 | Dynavax Tech Corp | Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür |
DE60036950T2 (de) | 1999-08-27 | 2008-08-07 | Inex Pharmaceuticals Corp., Burnaby | Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort |
US6165726A (en) | 1999-09-21 | 2000-12-26 | Ut-Battelle, Llc | Non-radioactive methods for chemical cleavage sequencing and footprinting of nucleic acids |
AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
MXPA02003059A (es) * | 1999-09-27 | 2002-09-30 | Univ Iowa Res Found | Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador. |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
AU2593701A (en) | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
ATE378348T1 (de) | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
CA2398432C (en) | 2000-01-26 | 2012-06-19 | Hybridon, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
US6552006B2 (en) * | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
EP1259264A4 (de) | 2000-02-23 | 2005-08-31 | Univ California | VERFAHREN ZUR BEHANDLUNG VON ENTZüNDLICHEN DARMERKRANKUNGEN UND ANDEREN FORMEN VON GASTROINTESTINALEN ENTZüNDUNGEN |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20020028784A1 (en) | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
AU2001249609A1 (en) | 2000-03-28 | 2001-10-08 | Department Of Veterans Affairs | Methods for increasing a cytotoxic T lymphocyte response in vivo |
EP1278550A4 (de) | 2000-04-07 | 2004-05-12 | Univ California | Synergistische verbesserungen von polynucleotid impfstoffen |
CA2407942A1 (en) | 2000-05-01 | 2001-11-08 | Hybridon, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
EP1292331A2 (de) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunstimulierende rns/dns hybridmolekule |
JP2005512499A (ja) | 2000-09-01 | 2005-05-12 | エピゲノミクス アーゲー | 進行中の疾病または特定の疾病の発病素質の診断 |
WO2002026757A2 (en) | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
KR100343935B1 (ko) * | 2000-10-09 | 2002-07-20 | 주식회사 하이닉스반도체 | Imt-2000 시스템내 atm 교환기에서의 dbwrr 셀스케줄링 장치 및 방법 |
EP1985702A3 (de) | 2000-12-08 | 2010-08-18 | Coley Pharmaceutical GmbH | CPG-ähnliche Nukleinsäuren und Verwendungsverfahren dafür |
US6882625B2 (en) * | 2000-12-14 | 2005-04-19 | Nokia Networks Oy | Method for scheduling packetized data traffic |
EP1364010B1 (de) | 2000-12-27 | 2010-06-16 | Dynavax Technologies Corporation | Immunomodulatorische polynukleotide und verfahren zur deren verwendung |
WO2002074922A2 (en) | 2001-03-16 | 2002-09-26 | The Regents Of The University Of California | Compositions and methods for modulating an immune response |
US7105495B2 (en) * | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US7176296B2 (en) * | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US20040132677A1 (en) * | 2001-06-21 | 2004-07-08 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same-IV |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
EP2423335B1 (de) * | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür |
US20030133988A1 (en) * | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
SG177000A1 (en) * | 2001-08-17 | 2012-01-30 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
KR20050009697A (ko) * | 2002-04-22 | 2005-01-25 | 바이오니취 라이프 사이언시즈 인코포레이티드 | 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도 |
NZ538628A (en) | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
EP1575977B1 (de) * | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung |
EP2094849B1 (de) * | 2006-11-09 | 2014-01-08 | Dynavax Technologies Corporation | Langfristige modifikation einer erkrankung mithilfe immunstimulatorischer oligonukleotide |
-
2003
- 2003-12-18 EP EP03814325A patent/EP1575977B1/de not_active Expired - Lifetime
- 2003-12-18 NZ NZ541027A patent/NZ541027A/en not_active IP Right Cessation
- 2003-12-18 US US10/741,720 patent/US7745606B2/en active Active
- 2003-12-18 KR KR1020127008544A patent/KR101309501B1/ko active IP Right Grant
- 2003-12-18 DK DK08013086.7T patent/DK1992635T3/da active
- 2003-12-18 AT AT08013086T patent/ATE544772T1/de active
- 2003-12-18 SG SG2011035342A patent/SG2011035342A/en unknown
- 2003-12-18 SI SI200331695T patent/SI1575977T1/sl unknown
- 2003-12-18 CN CN2009101704063A patent/CN101693890B/zh not_active Expired - Lifetime
- 2003-12-18 DE DE60329223T patent/DE60329223D1/de not_active Expired - Lifetime
- 2003-12-18 ES ES08013086T patent/ES2381309T3/es not_active Expired - Lifetime
- 2003-12-18 ES ES03814325T patent/ES2328807T3/es not_active Expired - Lifetime
- 2003-12-18 AU AU2003297483A patent/AU2003297483B2/en not_active Expired
- 2003-12-18 KR KR1020057011912A patent/KR101178816B1/ko active IP Right Grant
- 2003-12-18 JP JP2005510051A patent/JP5102959B2/ja not_active Expired - Lifetime
- 2003-12-18 KR KR1020127025824A patent/KR20120128729A/ko not_active Application Discontinuation
- 2003-12-18 CN CNB2003801073014A patent/CN100546998C/zh not_active Expired - Lifetime
- 2003-12-18 WO PCT/US2003/041001 patent/WO2004058179A2/en active Application Filing
- 2003-12-18 CA CA2511475A patent/CA2511475C/en not_active Expired - Lifetime
- 2003-12-18 EP EP08013086A patent/EP1992635B1/de not_active Expired - Lifetime
- 2003-12-18 SG SG2007045727A patent/SG173219A1/en unknown
- 2003-12-18 DK DK03814325T patent/DK1575977T3/da active
- 2003-12-18 AT AT03814325T patent/ATE442376T1/de active
- 2003-12-18 PT PT08013086T patent/PT1992635E/pt unknown
- 2003-12-18 PT PT03814325T patent/PT1575977E/pt unknown
-
2009
- 2009-05-18 HK HK09104499.9A patent/HK1125943A1/xx not_active IP Right Cessation
- 2009-11-25 CY CY20091101221T patent/CY1109642T1/el unknown
-
2011
- 2011-12-16 JP JP2011276052A patent/JP2012070757A/ja active Pending
-
2012
- 2012-04-25 CY CY20121100394T patent/CY1112704T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1125943A1 (en) | Immunostimulatory sequence oligonucleotides and methods of using the same | |
EP2423335A3 (de) | Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür | |
ATE471374T1 (de) | Immunomodulatorische polynukleotide und verfahren zur deren verwendung | |
WO2004058159A3 (en) | Branched immunomodulatory compounds and methods of using the same | |
IL157347A0 (en) | Organism authenticating apparatus | |
AU2003220373A1 (en) | Airbag tether retainer | |
GB0112343D0 (en) | Well treatment | |
TW511649U (en) | Wafer retainer | |
EP1225507A3 (de) | Pseudozahlengeneriergerät oder dieses verwendende Enkryptions- oder Dekryptionsgerät | |
WO2004053086A3 (en) | Plasmodium falciparum antigens and methods of use | |
EP1465699A4 (de) | Photophoretische autoimmunstimulation | |
GB0127384D0 (en) | Well treatment system | |
WO2003014323A3 (en) | Human smooth muscle myosin heavy chain | |
HK1049477A1 (en) | Apparatus for beauty treatment. | |
CY1114782T1 (el) | Χιμαιρικες ανοσορρυθμιστικες ενωσεις και μεθοδοι χρησης αυτων | |
SI1992635T1 (sl) | Imunostimulirni sekvenčni oligonukleotidi in postopki za njihovo uporabo | |
AU2002352667A1 (en) | Chemical treatment system using ozone | |
AUPR258501A0 (en) | Improved hide treatment | |
GB2413797B (en) | Microorganisms for well treatment | |
AU2003303227A8 (en) | An immunomodulatory protein derived from trypanosomes and uses thereof | |
GB0123302D0 (en) | Cipher apparatus | |
WO2005001060A3 (en) | Novel calcium channel | |
AU2002305374A1 (en) | Stimulation apparatus | |
GB0110191D0 (en) | Sterilization method | |
PL346099A1 (en) | Draught generating apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20231215 |